Table des Matières
Publicité
1. Lobatón T, López-García A, Rodríguez-Moranta F,
et al. A new rapid test for fecal calprotectin pre-
dicts endoscopic remission and postoperative
recurrence in Crohn's disease. J Crohns Colitis.
2013, 7(12):e641-51.
2. Lobatón Ortega T, Rodríguez-Moranta F, Lopez A,
et al. A new rapid quantitative test for fecal
calprotectin predicts endoscopic activity in ulce-
rative colitis. Inflamm Bowel Dis. 2013,
19(5):1034-42.
3. Wright EK, Kamm MA, De Cruz P, et al., Measure-
ment of fecal calprotectin improves monitoring
and detection of recurrence of Crohn's disease
after
surgery.
148(5):938-947.
4. Naismith GD, Smith LA, Barry SJ et al. A prospec-
tive evaluation of the predictive value of faecal
calprotectin in quiescent Crohn's disease. J
Crohns Colitis. 2014, 8(9):1022-9.
5. Ferreiro-Iglesias R, Barreiro-de Acosta M, Loren-
zo-Gonzalez A et al. Usefulness of a rapid faecal
calprotectin test to predict relapse in Crohn's
disease patients on maintenance treatment with
adalimumab. Scand J Gastroenterol. 2015,
23:1-6.
6. Ferreiro-Iglesias R1, Barreiro-de Acosta M, Otero
Santiago M, Lorenzo Gonzalez A, Alonso de la
Peña C, Benitez Estevez AJ, Dominguez-Muñoz JE.
Fecal calprotectin as Predictor of Relapse in
Patients With Inflammatory Bowel Disease Under
Maintenance Infliximab Therapy. J Clin Gastroen-
terol. 2015, 50(2):147-51.
7. Guardiola J., Lobatón T, Rodríguez-Alonso L, et
al. Fecal Level of calprotectin Identifies Histolo-
gic Inflammation in Patients with Ulcerative
Colitis In Clinical And Endoscopic Remission. Cli-
nical Gastroenterology and Hepatology 2014,
12(11):1865-70.
LF-IBDOC8
BIBLIOGRAPHIE
Gastroenterology.
2015,
8. Lasson A, Öhman L, Stotzer PO et al. Pharmaco-
logical intervention based on fecal calprotectin
levels in patients with ulcerative colitis at high
risk of a relapse: A prospective, randomized,
controlled study. United European Gastroenterol
J. 2015 ;3(1):72-9.
9. Lin JF, Chen JM, Zuo JH et al. Meta-analysis: fecal
calprotectin for assessment of inflammatory
bowel disease activity. Inflamm Bowel Dis. 2014
Aug;20(8):1407-15.
10. Bressler B, Panaccione R, Fedorak RN, et al. Cli-
nicians' guide to the use of fecal calprotectin to
identify and monitor disease activity in inflam-
matory bowel disease. Can J Gastroenterol Hepa-
tol. 2015, 29(7):369-72.
11. Peyrin-BL, Sandborn W, Sands BE et al. Selecting
Therapeutic Targets in Inflammatory Bowel
Disease (STRIDE): Determining Therapeutic Goals
for Treat-to-Target. Am J Gastroenterol. 2015,
110:1324-38
12. Molander P, Färkkiläb M, Ristimäkic A, et al. Does
Fecal calprotectin Predict Short-Term Relapse
After Stopping Tnfalpha-Blocking Agents In
Inflammatory Bowel Disease Patients In Deep
Remission? Journal of Crohn's and Colitis, 2015,
33–40.
13. De Vos M, Dewit O, D'Haens G et al. Consecutive
fecal calprotectin measurements to predict
relapse in patients with ulcerative colitis recei-
ving infliximab maintenance therapy. Inflamm
Bowel Dis. 2013, 9:2111-2117.
14. Fagerberg UL, Lööf L, Myrdal U et al. Colorectal
inflammation is well predicted by fecal calpro-
tectin in children with gastrointestinal symp-
toms. J Pediatr Gastroenterol Nutr. 2005,
40(4):450-5.
15. Kapel N, Campeotto F, Kalach N et al. Faecal
calprotectin in term and preterm neonates. J
Pediatr Gastroenterol Nutr. 2010 51(5):542-7.
31/32
Date de Révision: 22-01-2019
Publicité
Table des Matières
